Since the advent almost 25 years ago of techniques that enable simultaneous measurement of gene expression in a single sample, the use of gene expression profile combinations to understand tumour biology has promised to revolutionise our approach to diagnosis and prognosis in the clinic. However, this potential has yet to be fully realised despite the exponential increase in genomic data during this period.
A strategic approach for biomarker discovery aligned with the development and validation path of the therapeutic is essential. Almac Diagnostics Services has substantial expertise in biomarker discovery from gene expression, taking them beyond the proof-of-concept phase to analytically validate and deliver prospectively for clinical trial stratification.
This webinar explores some of the challenges that have hindered progress and discusses bioinformatics innovations with case study examples that may yet fuel a rise in successful translation of gene signatures into clinical application.
Dr. Laura Knight, VP of Data Sciences, Almac Diagnostic Services
Dr. Laura Knight is VP of Data Sciences within Almac Diagnostic Services. In this role, she leads a department of bioinformatics scientists, statisticians, and software developers providing technology integration and benchmarking, and supporting Almac Diagnostics Services’ Clients in the discovery, development and validation of biomarkers for clinical trial and CDx assays. Laura has a breadth of experience in the biomarker field with a strong interest in the application of machine learning techniques to gene expression data for biomarker discovery. Prior to joining Almac in 2009, Laura studied at Queen’s University Belfast and received a first-class Honours degree in Mathematics and Theoretical Physics before completing her PhD in Mathematics and Statistics with applied Bioinformatics, also from Queen’s University Belfast, where she currently holds an Honorary Lectureship position.
Who Should Attend?
This webinar will appeal to pharmaceutical companies and biotechnology companies and is relevant to both oncology and non-oncology indication focus. This webinar will benefit senior biopharma decision makers with responsibilities including, but not limited to:
- Data Sciences
- Biomarker Discovery
- Translational Medicine
- Clinical Development
- CDx Development
What You Will Learn
What you will learn:
- Challenges associated with analysing gene expression data
- Key study design considerations for biomarker discovery
- Best practices for training and validating a gene expression signature
- Making use of public data repositories and integrating different data types
- Innovative reporting of gene expression signatures using Almac’s proprietary bioinformatics software solution – claraT
The Almac Group
The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5,000 highly skilled personnel across 17 facilities including Europe, the US and Asia.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients. We will be exceptional, always.
Click here to find out more.
Your global partner for biomarker discovery, development & commercialisation.
Almac Diagnostic Services supports global pharma and biotech companies with their biomarker strategies from discovery through to companion diagnostic partnerships.
We have clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies.
The core services we offer fall into three main categories:
- Genomic Services
- Clinical Trial Assays
- Companion Diagnostics
Click here to find out more.